Microbio is pleased to announce the signing of a new distributor agreement with Iberlab, a trusted provider of advanced laboratory solutions, covering the territory of Portugal.
This partnership marks a significant step in Microbio’s mission to expand the reach of its flagship test, InfectID™-BSI, which enables the rapid and accurate detection of pathogens causing bloodstream infections, including life-threatening conditions like sepsis.
Meeting the Need for Fast and Accurate Pathogen Identification
InfectID™-BSI is a groundbreaking molecular diagnostic test that identifies 26 sepsis-associated pathogens, enabling clinicians to administer targeted treatment in less than three hours. The assay works by targeting the pathogen’s DNA ‘fingerprint’. Utilizing melt curve technology, InfectID™-BSI rapidly identifies sepsis-causing pathogens directly from blood samples. Without the need for enrichment or culture, this CE-marked product offers a powerful tool to improve patient outcomes through quicker and more accurate treatment, playing a crucial role in addressing sepsis, which contributes to millions of deaths globally each year.
Partnering with Iberlab to Bring InfectID™-BSI to Portugal
Under the terms of this agreement, Iberlab will act as Microbio’s exclusive distributor for Portugal, providing local expertise and support to ensure the successful adoption of InfectID™-BSI in laboratories across the country. Iberlab’s extensive experience in the diagnostic sector and their commitment to delivering cutting-edge solutions to healthcare providers aligns perfectly with Microbio’s goal of enhancing patient outcomes through innovation.
“We are very excited to partner with Iberlab as we continue to extend our presence in Europe,” said Johan Vanderhoeven, Chief Commercial Officer at Microbio. “Iberlab’s strong reputation and deep knowledge of the Portuguese diagnostics market make them the ideal partner to bring our InfectID™-BSI technology to new customers, ultimately helping to improve the detection and treatment of serious infections.”
João Teixeira, CEO of Iberlab, said, “We are thrilled about the opportunity to work with a company as innovative and capable as Microbio.”
This agreement follows several strategic partnerships across Europe and beyond, reinforcing Microbio’s commitment to global expansion and delivering diagnostic solutions that meet the evolving needs of healthcare professionals.